Johnson Pharmacare (532154) Q4 14/15 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 14/15 earnings summary
14 Oct, 2026Executive summary
No business activity in FY15 amid financial crisis and working-capital scarcity; operating revenue was nil and the year ended with a net loss of Rs 737,735.
Management was seeking an opportunity to restart operations and had undertaken cost-cutting measures.
Financial highlights
Revenue from operations and total revenue were nil in FY15, versus Rs 17,910,197,106 in FY14; FY14 purchases of stock-in-trade were also Rs 17,909,449,084.
Net loss was Rs 737,735 in FY15, compared with Rs 830,871 in FY14; FY15 basic and diluted EPS were both (Rs 0.01), versus (Rs 0.02).
Cash losses were Rs 223,734 in FY15; the audit annexure also notes losses in the immediately preceding year.
Outlook and guidance
Future development depended on commencement of operations; management was evaluating opportunities and pursuing feasible cost reductions.
Latest events from Johnson Pharmacare
- Working-capital constraints and share-sale losses accompanied a Rs 129.14 lakh FY23 net loss.532154
Q4 22/23 - A small profit returned, but working-capital scarcity kept operations largely dormant.532154Q4 20/21
- Rs 32.63m revenue and Rs 0.97m profit, but scarce working capital constrained operations.532154Q4 21/22
- No operations, zero revenue and a Rs 918,050 loss amid working-capital constraints.532154Q4 19/20
- A smaller loss offered little relief as working-capital scarcity kept operations inactive.532154Q4 18/19
- Nil operating revenue and working-capital scarcity defined FY2017-18.532154Q4 17/18
- Inactive operations and working-capital scarcity drove a ₹752,769 FY17 loss.532154Q4 16/17
- No revenue, a ₹1.26 million loss, and scarce working capital stalled operations.532154Q4 15/16
- Revenue reached ₹17.91bn, but losses, cash burn and a debt repayment default persisted.532154Q4 13/14